ZBIO Stock Summary and Trading Ideas (Zenas Biopharma | NASDAQ:ZBIO)

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Zenas Biopharma trades on the NASDAQ stock market under the symbol ZBIO.

As of November 13, 2026, ZBIO stock price climbed to $28.01 with 289,906 million shares trading.

ZBIO has a beta of -0.10, meaning it tends to be less sensitive to market movements. ZBIO has a correlation of 0.00 to the broad based SPY ETF.

ZBIO has a market cap of $1.83 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ZBIO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

ZBIO has underperformed the market in the last year with a price return of -21.8% while the SPY ETF gained +11.5%. ZBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.5% and -2.6%, respectively, while the SPY returned -2.1% and -1.9%, respectively.

ZBIO support price is $26.51 and resistance is $28.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZBIO shares will trade within this expected range on the day.